A traditional Chinese medicine composition for treating cerebrovascular diseases and a preparation method thereof

Abstract

The present application belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating cerebrovascular disease and a preparation method thereof. The traditional Chinese medicine composition for treating cerebrovascular disease comprises the following raw materials in parts by weight: 19-24 parts of chuanxiong, 15-20 parts of gastrodia, 8-14 parts of kudzu vine tea, 11-17 parts of San Ye Qing Teng, 3-9 parts of hibiscus flower, 7-12 parts of polygala, and 2-5 parts of licorice. The chuanxiong in the composition has the effects of activating blood and regulating qi, and the gastrodia has the effects of calming wind and stopping convulsion, and both of them are used as monarch drugs. The kudzu vine tea and San Ye Qing Teng are used as minister drugs, the kudzu vine tea has the effect of resolving and dredging collaterals, and the San Ye Qing Teng has the effect of dispelling wind and relieving pain. The hibiscus flower and polygala are both used as auxiliary drugs, and the licorice is used as a guide drug. The licorice can not only harmonize all drugs, but also warm the center and promote drug absorption. The traditional Chinese medicine composition has the effects of activating blood and resolving stasis, dredging collaterals and relieving pain, and soothing the nerves and helping sleep. The composition has good therapeutic effects on stroke and apoplexy.

Description

TECHNICAL FIELD

[0001] The application belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating cerebrovascular diseases and a preparation method thereof. BACKGROUND

[0002] Cerebrovascular diseases are mainly caused by occlusion of the middle cerebral artery, insufficient blood supply, hypoxia or hemorrhage, and belong to a common clinical disease, including ischemic stroke, hemorrhagic stroke and transient ischemic attack, etc. The disease has a high incidence, high disability rate and high mortality rate. In recent years, the incidence of stroke has been increasing year by year, and has surpassed cardiovascular diseases to become the first cause of death of residents, and shows a trend of youth. This kind of disease not only causes huge economic burden, but also seriously damages the quality of life of patients, leading to sequelae such as motor disorders, cognitive dysfunction, emotional disorders, etc. Among them, ischemic stroke accounts for a large proportion of cerebrovascular diseases, therefore, developing a method for treating cerebral ischemic stroke has important significance for treating cerebrovascular diseases.

[0003] Ischemic stroke is mainly caused by arterial stenosis due to thrombosis of the carotid artery system, or cerebral arterial embolism caused by unstable plaque rupture and shedding, and further causes insufficient blood perfusion in the brain, leading to ischemic and hypoxic injury of brain tissue. The disease is clinically often manifested as facial paralysis, hemiplegia and epilepsy and other symptoms of nerve function damage, and has become a common and frequently-occurring disease that seriously affects the quality of life of the elderly population. Its pathological process is closely related to neuroinflammation: microglial cells are activated, astrocytes are reactively proliferated, and a variety of pro-inflammatory cytokines including IL-8, TNF-α and TGF-β are released. These inflammatory responses exacerbate neuronal damage through different signaling pathways, promote cell death, and further worsen the progression of ischemic stroke. At present, the treatment of cerebrovascular diseases such as stroke / cerebral apoplexy in the clinic mainly tends to be western medicine treatment, and the commonly used drugs include antithrombotic drugs, neuroprotective agents, calcium antagonists, excitatory amino acid receptor antagonists, free radical scavengers, adenosine transport inhibitors, citicoline, gangliosides, nerve growth factors, leukocyte adhesion inhibitors, nitric oxide synthase inhibitors, anti-apoptotic drugs, and anti-inflammatory drugs. However, these drugs will have different degrees of side effects after long-term use, and due to the complex pathogenesis, the existing means have limited effect on the intervention of nerve function repair and inflammation control.

[0004] Traditional Chinese medicine has unique advantages of "overall regulation and multi-target intervention" in the prevention and treatment of cerebrovascular diseases. Traditional Chinese medicine theory believes that cerebrovascular diseases belong to the category of "stroke", and the core pathogenesis is "stagnation of blood and obstruction of collaterals, wind-phlegm disturbing the upper, and disorder of qi and blood". The acute stage is mainly "wind, fire, phlegm and blood stasis", and the recovery stage is mainly "qi deficiency and blood stasis, and deficiency of liver and kidney". The current treatment principle emphasizes "activating blood and resolving stasis, resolving phlegm and opening orifices, and supporting healthy qi and tonifying the root". However, the therapeutic effect of the treatment of ischemic stroke by using only blood-activating and phlegm-resolving drugs is still not ideal.

[0005] Therefore, it is of great significance to develop a safer and more effective traditional Chinese medicine composition for treating cerebral ischemia for the treatment of cerebrovascular diseases. SUMMARY

[0006] In order to overcome the shortcomings of the prior art, the primary purpose of the present application is to provide a traditional Chinese medicine composition for treating cerebrovascular diseases. The traditional Chinese medicine composition has the effects of activating blood and resolving stasis, dredging collaterals and relieving pain, calming the mind and improving sleep, and can be used for improving and treating diseases such as cerebral apoplexy and stroke.

[0007] Another purpose of the present application is to provide a preparation method of the traditional Chinese medicine composition for treating cerebrovascular diseases.

[0008] The purpose of the present application is achieved by the following technical scheme:

[0009] A traditional Chinese medicine composition for treating cerebrovascular diseases, comprising the following raw materials in parts by weight: 19-24 parts of Chuanxiong Rhizoma, 15-20 parts of Gastrodia, 8-14 parts of Ampelopsis grossedentata, 11-17 parts of Caulis Lonicerae Japonicae, 3-9 parts of Hibiscus, 7-12 parts of Polygala, and 2-5 parts of Glycyrrhiza.

[0010] Further, the traditional Chinese medicine composition for treating cerebrovascular diseases comprises the following raw materials in parts by weight: 20 parts of Chuanxiong Rhizoma, 18 parts of Gastrodia, 12 parts of Ampelopsis grossedentata, 15 parts of Caulis Lonicerae Japonicae, 7 parts of Hibiscus, 10 parts of Polygala, and 3 parts of Glycyrrhiza.

[0011] The preparation method of the traditional Chinese medicine composition for treating cerebrovascular diseases comprises the following steps:

[0012] (1) The raw materials are weighed according to the weight parts, crushed and sieved, then mixed uniformly, and soaked in water to obtain a mixed solution; after the soaking treatment is completed, the mixed solution is boiled, filtered to obtain a first filtrate and a first residue;

[0013] (2) The first residue is soaked, boiled and filtered in water to obtain a second filtrate and a second residue;

[0014] (3) The first filtrate and the second filtrate are combined, concentrated under reduced pressure, and the concentrated solution is collected, and a pharmaceutically acceptable adjuvant is added to the concentrated solution to prepare a preparation, thereby obtaining the traditional Chinese medicine composition for treating cerebrovascular diseases.

[0015] Further, in step (1), the particle size of the crushed raw medicine is 50-80 mesh.

[0016] Further, in step (1), the solid-liquid ratio of the raw medicine and water is 1g:(5-10)mL.

[0017] Further, in step (2), the solid-liquid ratio of the first filter residue and water is 1g:(6-8)mL.

[0018] Further, the soaking time in step (1) and step (2) is 1-2h.

[0019] Further, the decocting time in step (1) and step (2) is 2-3h.

[0020] Further, the volume of the concentrated liquid corresponding to each gram of raw medicine is 3-5mL.

[0021] Further, the dosage form of the preparation is any one of capsule, granule, oral liquid, and tablet.

[0022] In order to more easily understand the present application, the efficacy of each raw material in the present application is described herein:

[0023] Chuanxiong: bitter, pungent, slightly numb, slightly sweet, warm. Liver, gallbladder, pericardium meridian. It has the effect of promoting blood circulation and qi, dispelling wind and relieving pain, and is used for chest and spleen pain, chest and rib pain.

[0024] Gastrodia: sweet, flat; liver meridian. It is listed as a substance that is both food and traditional Chinese medicine according to tradition. Function and indication: wind-stopping, calming liver yang, dispelling wind and dredging collaterals. "Yongfang Faxiang" records "treatment of adult wind-heat headache; infantile wind convulsion and palpitation; various wind paralysis and numbness; wind-heat language disorder."

[0025] Rattan tea: bitter, slightly astringent, cool. Its sweet and cool taste has the effects of clearing heat and resolving toxins, antibacterial and anti-inflammatory, dispelling wind and dampness, strengthening bones and muscles, lowering blood pressure, lowering blood lipids, protecting liver, etc. It is used for dysentery, diarrhea, urinary pain, high blood pressure, dizziness and eye swelling, sprains and injuries. "Hubei Chinese Herbal Medicine Records" records "clearing heat and cooling blood. Used for high blood pressure, dizziness and eye swelling, etc."

[0026] Three-leaf green vine: pungent, slightly sweet, astringent, warm. It has the effects of clearing heat and resolving toxins, dispelling wind and reducing phlegm, promoting blood circulation and relieving pain, and dissipating blood stasis and swelling. Soaking in wine and rubbing on the affected area can treat rheumatoid arthritis, sprains and injuries, poliomyelitis sequelae, insect and snake bites, etc. Three-leaf green vine root decoction with rice wine can treat bone fracture and swelling.

[0027] Hibiscus: sweet, flat, non-toxic. Heart; lung; liver; spleen. Has the effect of clearing the lungs, phlegm, cooling blood, detoxification. Can treat phlegm fire cough, nosebleeds, dysentery, red and white turbidity, carbuncle, toxic sore. The blood-cooling and detoxification of Luchuan Bencao is recorded. Treat blood heat, bleeding, blood itching, toxic sore.

[0028] Polygala: flat, sweet. Return to stomach, spleen, lung. Known as the king of herbs. Pharmacologically has the effects of clearing heat and detoxifying, tonifying spleen and invigorating qi, relieving pain, relieving cough, detoxifying, regulating drug properties. Used for the treatment of spleen and stomach weakness, fatigue, palpitation and shortness of breath, stomach and abdominal pain, and relief of drug toxicity and food poisoning. The Bencao Jing records: treat five zang organs and six fu organs cold and heat evil, strengthen bones and muscles, increase strength, detoxify.

[0029] Licorice: flat, sweet. Return to stomach, spleen, lung. Has the effects of clearing heat and detoxifying, tonifying spleen and invigorating qi, relieving pain, relieving cough, detoxifying, regulating drug properties.

[0030] The present application has the following effects relative to the prior art:

[0031] In the formula, Szechuan lovage rhizome promotes blood circulation and regulates qi, Gastrodia elata relieves convulsions and stops convulsions, both of which are used as monarch drugs; with Ampelopsis megalophylla and three-leaf green vine as minister drugs, Ampelopsis megalophylla disperses and dredges collaterals, and three-leaf green vine expels wind and relieves pain; Hibiscus flower regulates the wet and regulates the period, Polygala soothes the nerves and helps sleep, both of which are auxiliary drugs, and licorice is the servant drug, which not only regulates the drugs, but also warms the middle and promotes drug absorption. The drug monarch, minister, auxiliary and servant in the formula are properly matched, so that the drugs are matched with each other, and the effects of promoting blood circulation and removing blood stasis, dredging collaterals and relieving pain, soothing nerves and helping sleep are integrated. The test proves that it also has the effects of reducing inflammatory response and improving nervous system function, and has good therapeutic effect on cerebral apoplexy, cerebral stroke and other syndromes. DETAILED DESCRIPTION

[0032] The present application will be further described in conjunction with the following examples, but the embodiments of the present application are not limited thereto. Unless otherwise specified, the reagents, methods and equipment used in the present application are conventional reagents, methods and equipment in the technical field. The test methods in the following examples are not specified, which are usually carried out according to conventional experimental conditions or according to the experimental conditions recommended by the manufacturer. Unless otherwise specified, the reagents and raw materials used in the present application are commercially available.

[0033] Example 1

[0034] A traditional Chinese medicine composition for treating cerebrovascular disease, comprising the following raw materials by weight: Szechuan lovage rhizome 20 parts, Gastrodia elata 18 parts, Ampelopsis megalophylla 12 parts, three-leaf green vine 15 parts, Hibiscus flower 7 parts, Polygala 10 parts, and licorice 3 parts.

[0035] The preparation method of the traditional Chinese medicine composition for treating cerebrovascular disease comprises the following steps:

[0036] (1) according to the weight parts of each raw drug, after crushing and sieving, mix evenly, the particle size of the crushed raw drug is 70 mesh; then soak in water for 1.5h, the solid-liquid ratio of the raw drug and water is 1g:8mL, to obtain a mixed solution; after soaking, the mixed solution is boiled for 2.5h, and then filtered to obtain a first filtrate and a first residue;

[0037] (2) soak the first residue in water for 1.5h, the solid-liquid ratio of the first residue and water is 1g:7mL; boil for 2.5h, filter to obtain a second filtrate and a second residue;

[0038] (3) combine the first filtrate and the second filtrate, concentrate under reduced pressure, collect the concentrated solution, the volume of the concentrated solution corresponding to each gram of raw drug is 4mL, add a pharmaceutically acceptable excipient to the concentrated solution to prepare a capsule, and the capsule is obtained.

[0039] Example 2

[0040] A traditional Chinese medicine composition for treating cerebrovascular disease, including the following raw materials in weight parts: Chuanxiong 19 parts, Gastrodia 15 parts, Kudzu 8 parts, San Ye Qing 11 parts, Jushihua 3 parts, Fuling 7 parts, and Gancao 2 parts.

[0041] The preparation method of the above-mentioned traditional Chinese medicine composition for treating cerebrovascular disease, including the following steps:

[0042] (1) according to the weight parts of each raw drug, after crushing and sieving, mix evenly, the particle size of the crushed raw drug is 50 mesh; then soak in water for 1h, the solid-liquid ratio of the raw drug and water is 1g:5mL, to obtain a mixed solution; after soaking, the mixed solution is boiled for 2h, and then filtered to obtain a first filtrate and a first residue;

[0043] (2) soak the first residue in water for 1h, the solid-liquid ratio of the first residue and water is 1g:6mL; boil for 2h, filter to obtain a second filtrate and a second residue;

[0044] (3) combine the first filtrate and the second filtrate, concentrate under reduced pressure, collect the concentrated solution, the volume of the concentrated solution corresponding to each gram of raw drug is 3mL, add a pharmaceutically acceptable excipient to the concentrated solution to prepare a capsule, and the capsule is obtained.

[0045] Example 3

[0046] A traditional Chinese medicine composition for treating cerebrovascular disease, including the following raw materials in weight parts: Chuanxiong 24 parts, Gastrodia 20 parts, Kudzu 14 parts, San Ye Qing 17 parts, Jushihua 9 parts, Fuling 12 parts, and Gancao 5 parts.

[0047] The preparation method of the above-mentioned traditional Chinese medicine composition for treating cerebrovascular disease, including the following steps:

[0048] (1) The raw medicinal materials are weighed according to the weight parts, mixed uniformly after being crushed and sieved, and the particle size of the crushed raw medicinal materials is 80 meshes; then water is added for soaking treatment for 2 h, wherein the solid-liquid ratio of the raw medicinal materials and water is 1 g: 10 mL, to obtain a mixed solution; after the soaking treatment, the mixed solution is boiled for 3 h, and after filtration, a first filtrate and a first filter residue are obtained;

[0049] (2) The first filter residue is soaked in water for 2 h, and the solid-liquid ratio of the first filter residue and water is 1 g: 8 mL; boiling is performed for 3 h, and after filtration, a second filtrate and a second filter residue are obtained;

[0050] (3) The first filtrate and the second filtrate are combined, concentrated under reduced pressure, and the concentrated solution is collected, wherein the volume of the concentrated solution corresponding to 1 g of raw medicinal materials is 5 mL; a pharmaceutically acceptable excipient is added to the concentrated solution to prepare a capsule, and the capsule is obtained.

[0051] Comparative Example 1

[0052] The traditional Chinese medicine composition of the present comparative example comprises the following raw materials in weight parts: Chuanxiong 20 parts, Tianma 18 parts, San Ye Qingteng 15 parts, Zhujin Flower 7 parts, Yuanzhi 10 parts, and Gancao 3 parts. That is, the addition of Tengcha is omitted in the formula; the others remain the same as in Example 1.

[0053] Comparative Example 2

[0054] The traditional Chinese medicine composition of the present comparative example comprises the following raw materials in weight parts: Chuanxiong 20 parts, Tianma 18 parts, Tengcha 12 parts, Zhujin Flower 7 parts, Yuanzhi 10 parts, and Gancao 3 parts. That is, the addition of San Ye Qingteng is omitted in the formula; the others remain the same as in Example 1.

[0055] Comparative Example 3

[0056] The traditional Chinese medicine composition of the present comparative example comprises the following raw materials in weight parts: Chuanxiong 20 parts, Tianma 18 parts, Tengcha 12 parts, Jixueteng 15 parts, Zhujin Flower 7 parts, Yuanzhi 10 parts, and Gancao 3 parts. That is, San Ye Qingteng in the formula is replaced by Jixueteng; the others remain the same as in Example 1.

[0057] Comparative Example 4

[0058] The traditional Chinese medicine composition of the present comparative example comprises the following raw materials in weight parts: Chuanxiong 20 parts, Tianma 18 parts, Tengcha 12 parts, San Ye Qingteng 15 parts, Yuanzhi 10 parts, and Gancao 3 parts. That is, the addition of Zhujin Flower is omitted in the formula; the others remain the same as in Example 1.

[0059] Comparative Example 5

[0060] A Chinese medicine composition for treating cerebrovascular disease, comprising the following raw materials in parts by weight: Chuanxiong 20 parts, Gastrodia 18 parts, Tengcha 12 parts, Sanyeqingteng 15 parts, Chishao 7 parts, Fuling 10 parts, Gancao 3 parts. The Jujinhuas in the formula are replaced by Chishao; the rest is the same as Example 1.

[0061] Test Example 1

[0062] In order to verify the safety of the Chinese medicine compositions in Examples 1-3, the following experiment was conducted:

[0063] Male SD rats with a body weight of 200±20g were selected as test animals, purchased from Zhengzhou Huiji District Huaxing Experimental Animal Breeding Farm; SPF level, 12h light / 12h dark cycle alternation, the feeding temperature was 23±2℃, the relative humidity was 50±5%, and the adaptive feeding was carried out for one week. The SD rats were randomly divided into Example 1, Example 2, Example 3, blank control group, 6 in each group, respectively, 5g / kg (calculated by crude drug) of the Chinese medicine compositions in Examples 1-3 were administered by gavage, one group was administered with the same volume of normal saline as a blank control group, and the rats were fed in separate cages, and observed for 28d.

[0064] Compared with the blank control group, after the rats were administered with the Chinese medicine compositions in Examples 1-3 of the present application, the behavior activity, urination and defecation, drinking and eating, and mental state of the rats were good, and there was no death phenomenon. It shows that the Chinese medicine composition of the present application has high safety for SD rats.

[0065] Test Example 2

[0066] In order to explore the effects of the Chinese medicine compositions in Examples 1-3 and Comparative Examples 1-5 on cerebral ischemic rats, the following experiment was conducted:

[0067] 1. Test animals

[0068] Male SD rats with a body weight of 200±20g were selected as test animals, purchased from Zhengzhou Huiji District Huaxing Experimental Animal Breeding Farm; SPF level, randomly divided into 13 groups, 10 in each group. Keep 12h light / 12h dark cycle alternation, the feeding temperature was 23±2℃, the relative humidity was 50±5%, and the adaptive feeding was carried out for one week. The animals were fasted for 12h before the experiment.

[0069] 2. Construction of animal model

[0070] Take 12 groups of SD rats (120), using a line plug method to construct SD rat cerebral artery occlusion caused by cerebral ischemia model, according to the dose of 50 mg / kg intraperitoneal injection of su Tai anesthesia SD rats, the anesthetized rats supine fixed on the operating table, in the neck area of rats shaved, and using iodophor disinfection, in the median line of the neck right side to do surgical incision. Incision of skin and superficial fascia, separation between the two submaxillary glands between the organization. Separation of the rat common carotid artery (CCA), external carotid artery (ECA) and internal carotid artery (ICA). In the distal end of ECA and CCA ligation; at the same time with the artery clamp clamp ICA. In ECA residual end cut a 0.2 mm small mouth, a sterilized nylon line through the incision into the CCA bifurcation, and then through the ECA gently into the ICA, release the ICA on the artery clamp, until feeling a slight resistance, at this time the insertion length is about 18-19 mm, release the CCA on the artery clamp, after the operation is completed, suture incision skin, each rat muscle injection of 10,000 units of penicillin, once a day, for 3 days.

[0071] 3. Animal grouping

[0072] The above 12 groups of SD rats were randomly divided into model group, positive drug group, example 1 low dose group, example 1 middle dose group, example 1 high dose group, example 2 low dose group, example 3 low dose group, comparative example 1 low dose group, comparative example 2 low dose group, comparative example 3 low dose group, comparative example 4 low dose group, comparative example 5 low dose group. In addition to 1 group of SD rats without any treatment as a blank control group.

[0073] 4. Drug treatment

[0074] Example 1 low dose group: with crude drug, gavage 0.5 g / kg of traditional Chinese medicine composition of example 1, 1 time / d, continuous administration for 21 days;

[0075] Example 1 middle dose group: with crude drug, gavage 1.0 g / kg of traditional Chinese medicine composition of example 1, 1 time / d, continuous administration for 21 days;

[0076] Example 1 high dose group: with crude drug, gavage 2.0 g / kg of traditional Chinese medicine composition of example 1, 1 time / d, continuous administration for 21 days;

[0077] Example 2 low dose group: with crude drug, gavage 0.5 g / kg of traditional Chinese medicine composition of example 2, 1 time / d, continuous administration for 21 days;

[0078] Example 3 low dose group: with crude drug, gavage 0.5 g / kg of traditional Chinese medicine composition of example 3, 1 time / d, continuous administration for 21 days;

[0079] Comparative Example 1 low-dose group: intragastrically administered 0.5 g / kg of the traditional Chinese medicine composition of Comparative Example 1 in crude drug, once a day, for 21 days of continuous administration;

[0080] Comparative Example 2 low-dose group: intragastrically administered 0.5 g / kg of the traditional Chinese medicine composition of Comparative Example 2 in crude drug, once a day, for 21 days of continuous administration;

[0081] Comparative Example 3 low-dose group: intragastrically administered 0.5 g / kg of the traditional Chinese medicine composition of Comparative Example 3 in crude drug, once a day, for 21 days of continuous administration;

[0082] Comparative Example 4 low-dose group: intragastrically administered 0.5 g / kg of the traditional Chinese medicine composition of Comparative Example 4 in crude drug, once a day, for 21 days of continuous administration;

[0083] Comparative Example 5 low-dose group: intragastrically administered 0.5 g / kg of the traditional Chinese medicine composition of Comparative Example 5 in crude drug, once a day, for 21 days of continuous administration;

[0084] Positive drug group: intragastrically administered 10 mg / kg of nimodipine solution, once a day, for 21 days of continuous administration;

[0085] Blank control group and model group: intragastrically administered the same amount of normal saline, once a day, for 21 days of continuous administration.

[0086] 5. Index test

[0087] 5.1, SD rat neurological function score test: the signs of SD rats were observed 24 hours after the last day of administration, and then the neurological function score was performed: 0 level: no neurological dysfunction, recorded as 0 points; unable to stretch the paralyzed forelimb recorded as 1 point, rotated to the hemiplegic side recorded as 2 points, fell to the hemiplegic side recorded as 3 points, no autonomous activity, and loss of consciousness recorded as 4 points. The experimental results are shown in Table 1.

[0088] Table 1. Neurological function score results of traditional Chinese medicine composition in different groups

[0089]

[0090] According to the test results in Table 1, compared with the blank control group, the neurological function score level of the model group rats was significantly increased 24 hours after administration. Compared with the model group, the neurological function score of the rats in the example group was significantly reduced. The above test results prove that the behavioral performance of rats is significantly improved after intervention by the traditional Chinese medicine composition, which provides a theoretical basis for the clinical treatment of ischemic stroke.

[0091] 5.2, after the last administration, SD rats were fasted for 12h, during which they were not allowed to drink water, each SD rat was injected intraperitoneally with Cetrotide at a dose of 50mg / kg, the rats were anesthetized, the abdominal aorta blood was taken, after centrifugation, the upper plasma was taken, according to the operation requirements of the ELISA kit instruction, the levels of tumor necrosis factor-α (TNF-α) and interleukin-8 (IL-8) inflammatory factors in the serum of SD rats were detected; the experimental results are shown in Table 2.

[0092] Table 2: IL-8 and TNF-α levels of different groups of traditional Chinese medicine compositions

[0093]

[0094] The process of stroke is closely related to the change of neural inflammatory factors, and the detection of IL-8 and TNF-α levels of animals is to directly evaluate whether the traditional Chinese medicine composition for treating cerebrovascular diseases can effectively inhibit the key and harmful neural inflammatory response after the occurrence of cerebrovascular diseases.

[0095] According to the test results in Table 2, compared with the blank control group, the IL-8 and TNF-α levels of the model group increased significantly, indicating that after the construction of the ischemic stroke model, the inflammatory response of the rats was aggravated. Compared with the model group, the IL-8 and TNF-α contents of the groups of each embodiment of the present application were significantly reduced, and were higher than those of the groups of comparative examples 1-5. The above results show that the traditional Chinese medicine composition of the present application can significantly reduce the contents of inflammatory factors IL-8 and TNF-α, and inhibit the reaction process of inflammatory factors, that is, the traditional Chinese medicine composition of the present application is beneficial to control the inflammatory response in the process of stroke, and can be used for treating stroke and effectively relieving the disease condition.

[0096] Compared with example 1, comparative examples 1-5 respectively omitted the rattan tea; omitted the San Yeqing rattan; replaced the San Yeqing rattan with the chicken blood rattan; omitted the Zhujin flower; and replaced the Zhujin flower with the red peony root. Although they can reduce the inflammatory level to different degrees, the effect is poor.

[0097] The above embodiments are only preferred embodiments of the present application, and cannot be used to limit the scope of protection of the present application, and any non-essential changes and substitutions made by those skilled in the art on the basis of the present application are within the scope of protection claimed by the present application.

Claims

1. A traditional Chinese medicine composition for treating cerebrovascular disease, characterized in that, Chuanxiong 19-24 parts, Gouteng 8-14 parts, Sanyeqingteng 11-17 parts, Honghua 3-9 parts, Rensheng 7-12 parts, Gancao 2-5 parts by weight.

2. The Chinese medicine composition for treating cerebrovascular disease according to claim 1, characterized in that, Chuanxiong 20 parts, Gouteng 12 parts, Sanyeqingteng 15 parts, Honghua 7 parts, Rensheng 10 parts, Gancao 3 parts by weight.

3. The preparation method of the traditional Chinese medicine composition for treating cerebrovascular disease according to claim 1 or 2, characterized in that, The method comprises the following steps: (1) each raw material is weighed according to the weight parts, crushed and sieved, then mixed uniformly, and soaked in water to obtain a mixed solution; after the soaking treatment is completed, the mixed solution is decocted, and a first filtrate and a first residue are obtained after filtration; (2) the first residue is soaked, decocted and filtered in water to obtain a second filtrate and a second residue; (3) the first filtrate and the second filtrate are combined, concentrated under reduced pressure, and the concentrated solution is collected; a pharmaceutically acceptable excipient is added to the concentrated solution to prepare a preparation, thereby obtaining the preparation.

4. The preparation method of the traditional Chinese medicine composition for treating cerebrovascular disease according to claim 3, characterized in that, In step (1), the particle size of the crushed raw material is 50-80 mesh.

5. The preparation method of the traditional Chinese medicine composition for treating cerebrovascular disease according to claim 3, characterized in that, In step (1), the solid-liquid ratio of the raw material to water is 1g:(5-10)mL.

6. The preparation method of the traditional Chinese medicine composition for treating cerebrovascular disease according to claim 3, characterized in that, In step (2), the solid-liquid ratio of the first residue to water is 1g:(6-8)mL.

7. The preparation method of the traditional Chinese medicine composition for treating cerebrovascular disease according to claim 3, characterized in that, The soaking time in steps (1) and (2) is 1-2h.

8. The preparation method of the traditional Chinese medicine composition for treating cerebrovascular disease according to claim 3, characterized in that, The decoction time in steps (1) and (2) is 2-3h.

9. A method for preparing a traditional Chinese medicine composition for treating cerebrovascular diseases according to claim 3, characterized in that, The volume of the concentrated solution corresponding to each gram of raw material is 3-5mL.

10. A method for preparing a traditional Chinese medicine composition for treating cerebrovascular diseases according to claim 3, characterized in that, The dosage form of the preparation is any one of a capsule, a granule, an oral solution and a tablet.

Images